Caspase-1 level is higher in the scalp in androgenetic alopecia

Juan Pablo P de Rivero Vaccari, Marty E. Sawaya, Frank Brand, Bernard P. Nusbaum, Alan J. Bauman, Helen Bramlett, W. Dalton Dietrich, Robert Keane

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Background and objectives Inflammasomes that activate caspase-1 govern the innate immune inflammatory response. Whether hair loss associated with androgenetic alopecia (AGA) involves caspase-1 activation is not known. Methods Immunohistochemical staining for caspase-1 was performed on scalp tissue sections, and protein lysates were analyzed from individuals with AGA (no treatment), and individuals with AGA taking finasteride with apparent hair growth, individuals with AGA taking finasteride without noted hair growth, and normal controls. In vitro studies of human keratinocytes were conducted to establish effects of finasteride, dihydrotestosterone (DHT), and testosterone on caspase-1 levels using immunoblot analysis. Results Caspase-1 is expressed in normal human adult epidermal keratinocytes. Caspase-1 expression is greater in men with AGA. In contrast, in men taking finasteride, caspase-1 levels were lower and were similar to those in normal controls. In vitro studies showed that keratinocytes treated with finasteride in combination with testosterone or DHT resulted in a significant decrease in caspase-1 expression. Conclusion In vivo and in vitro finasteride treatment resulted in lower caspase-1 expression, supporting the idea that androgens influence innate immunity involved in the hair cycle in AGA. These findings may provide a basis for development of novel treatments for inflammatory skin and hair diseases.

Original languageEnglish
Pages (from-to)1033-1039
Number of pages7
JournalDermatologic Surgery
Volume38
Issue number7 PART 1
DOIs
StatePublished - Jul 1 2012

Fingerprint

Caspase 1
Alopecia
Scalp
Finasteride
Keratinocytes
Hair
Dihydrotestosterone
Innate Immunity
Testosterone
Hair Diseases
Inflammasomes
Growth
Skin Diseases
Androgens
Therapeutics
Staining and Labeling

ASJC Scopus subject areas

  • Dermatology
  • Surgery

Cite this

Caspase-1 level is higher in the scalp in androgenetic alopecia. / de Rivero Vaccari, Juan Pablo P; Sawaya, Marty E.; Brand, Frank; Nusbaum, Bernard P.; Bauman, Alan J.; Bramlett, Helen; Dalton Dietrich, W.; Keane, Robert.

In: Dermatologic Surgery, Vol. 38, No. 7 PART 1, 01.07.2012, p. 1033-1039.

Research output: Contribution to journalArticle

de Rivero Vaccari, Juan Pablo P ; Sawaya, Marty E. ; Brand, Frank ; Nusbaum, Bernard P. ; Bauman, Alan J. ; Bramlett, Helen ; Dalton Dietrich, W. ; Keane, Robert. / Caspase-1 level is higher in the scalp in androgenetic alopecia. In: Dermatologic Surgery. 2012 ; Vol. 38, No. 7 PART 1. pp. 1033-1039.
@article{9eec5c11be7e4899a68506798aa6cf26,
title = "Caspase-1 level is higher in the scalp in androgenetic alopecia",
abstract = "Background and objectives Inflammasomes that activate caspase-1 govern the innate immune inflammatory response. Whether hair loss associated with androgenetic alopecia (AGA) involves caspase-1 activation is not known. Methods Immunohistochemical staining for caspase-1 was performed on scalp tissue sections, and protein lysates were analyzed from individuals with AGA (no treatment), and individuals with AGA taking finasteride with apparent hair growth, individuals with AGA taking finasteride without noted hair growth, and normal controls. In vitro studies of human keratinocytes were conducted to establish effects of finasteride, dihydrotestosterone (DHT), and testosterone on caspase-1 levels using immunoblot analysis. Results Caspase-1 is expressed in normal human adult epidermal keratinocytes. Caspase-1 expression is greater in men with AGA. In contrast, in men taking finasteride, caspase-1 levels were lower and were similar to those in normal controls. In vitro studies showed that keratinocytes treated with finasteride in combination with testosterone or DHT resulted in a significant decrease in caspase-1 expression. Conclusion In vivo and in vitro finasteride treatment resulted in lower caspase-1 expression, supporting the idea that androgens influence innate immunity involved in the hair cycle in AGA. These findings may provide a basis for development of novel treatments for inflammatory skin and hair diseases.",
author = "{de Rivero Vaccari}, {Juan Pablo P} and Sawaya, {Marty E.} and Frank Brand and Nusbaum, {Bernard P.} and Bauman, {Alan J.} and Helen Bramlett and {Dalton Dietrich}, W. and Robert Keane",
year = "2012",
month = "7",
day = "1",
doi = "10.1111/j.1524-4725.2012.02378.x",
language = "English",
volume = "38",
pages = "1033--1039",
journal = "Dermatologic Surgery",
issn = "1076-0512",
publisher = "Wiley-Blackwell",
number = "7 PART 1",

}

TY - JOUR

T1 - Caspase-1 level is higher in the scalp in androgenetic alopecia

AU - de Rivero Vaccari, Juan Pablo P

AU - Sawaya, Marty E.

AU - Brand, Frank

AU - Nusbaum, Bernard P.

AU - Bauman, Alan J.

AU - Bramlett, Helen

AU - Dalton Dietrich, W.

AU - Keane, Robert

PY - 2012/7/1

Y1 - 2012/7/1

N2 - Background and objectives Inflammasomes that activate caspase-1 govern the innate immune inflammatory response. Whether hair loss associated with androgenetic alopecia (AGA) involves caspase-1 activation is not known. Methods Immunohistochemical staining for caspase-1 was performed on scalp tissue sections, and protein lysates were analyzed from individuals with AGA (no treatment), and individuals with AGA taking finasteride with apparent hair growth, individuals with AGA taking finasteride without noted hair growth, and normal controls. In vitro studies of human keratinocytes were conducted to establish effects of finasteride, dihydrotestosterone (DHT), and testosterone on caspase-1 levels using immunoblot analysis. Results Caspase-1 is expressed in normal human adult epidermal keratinocytes. Caspase-1 expression is greater in men with AGA. In contrast, in men taking finasteride, caspase-1 levels were lower and were similar to those in normal controls. In vitro studies showed that keratinocytes treated with finasteride in combination with testosterone or DHT resulted in a significant decrease in caspase-1 expression. Conclusion In vivo and in vitro finasteride treatment resulted in lower caspase-1 expression, supporting the idea that androgens influence innate immunity involved in the hair cycle in AGA. These findings may provide a basis for development of novel treatments for inflammatory skin and hair diseases.

AB - Background and objectives Inflammasomes that activate caspase-1 govern the innate immune inflammatory response. Whether hair loss associated with androgenetic alopecia (AGA) involves caspase-1 activation is not known. Methods Immunohistochemical staining for caspase-1 was performed on scalp tissue sections, and protein lysates were analyzed from individuals with AGA (no treatment), and individuals with AGA taking finasteride with apparent hair growth, individuals with AGA taking finasteride without noted hair growth, and normal controls. In vitro studies of human keratinocytes were conducted to establish effects of finasteride, dihydrotestosterone (DHT), and testosterone on caspase-1 levels using immunoblot analysis. Results Caspase-1 is expressed in normal human adult epidermal keratinocytes. Caspase-1 expression is greater in men with AGA. In contrast, in men taking finasteride, caspase-1 levels were lower and were similar to those in normal controls. In vitro studies showed that keratinocytes treated with finasteride in combination with testosterone or DHT resulted in a significant decrease in caspase-1 expression. Conclusion In vivo and in vitro finasteride treatment resulted in lower caspase-1 expression, supporting the idea that androgens influence innate immunity involved in the hair cycle in AGA. These findings may provide a basis for development of novel treatments for inflammatory skin and hair diseases.

UR - http://www.scopus.com/inward/record.url?scp=84863720494&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84863720494&partnerID=8YFLogxK

U2 - 10.1111/j.1524-4725.2012.02378.x

DO - 10.1111/j.1524-4725.2012.02378.x

M3 - Article

C2 - 22404322

AN - SCOPUS:84863720494

VL - 38

SP - 1033

EP - 1039

JO - Dermatologic Surgery

JF - Dermatologic Surgery

SN - 1076-0512

IS - 7 PART 1

ER -